GoPath Exhibits at ASCO 2017 Annual Meeting

We were proud to exhibit at this year's ASCO Annual Meeting. The event took place at Chicago's McCormick Place Convention Center this past weekend and brought in approximately 38,000 oncologists from around the world.

During the meeting, we emphasized the release of our new testing series, OncoTarget™. Not only did we hand out brochures and show a digital presentation at our booth about this new NGS-based diagnostic, an article about GoPath's OncoTarget™ was featured on the cover of Monday's publication, Clinical Oncologist Daily.

We also debuted our new mobile app available at the App Store and Google Play. The app was available free for download at our booth via a QR code that attendees could easily scan in from their smartphones. This app gives users updates on company news, new test releases, updated requisitions and current product brochures and technical flyers.

In the technology realm, we also engaged in conversations about ASCO events on social media via the #ASCO17 hashtag. Overall, it was a great event to participate in and we'll be back next year!

GoPath Laboratories, a patient-centric molecular diagnostic and anatomic pathology laboratory, has focused its recent research & development efforts on creating two comprehensive cancer diagnostic platforms based on NGS technology: OncoTargetTM & GeneticsNowTM. These accomplishments have established GoPath as a leader in cutting-edge molecular cancer diagnostics with a goal of better serving clinicians, hospitals and pharmaceutical clients.

OncoTargetTM --GoPath’s highly-sensitive, NGS-based series--was created to examine the 88 well-characterized cancer genes found in solid tumors for point mutations, copy number alterations, microsatellite instability and rearrangements. This single, comprehensive assay provides oncologists with clinically-actionable data including a complete list of all identifiable genomic alterations, relevant FDA-approved drugs and current clinical trials specific to a patient’s cancer. The genes tested in OncoTarget™- 88 are of high clinical and biologic importance and are screened using NGS at extremely high coverage. GoPath also offers a version of OncoTarget™ via liquid biopsy. This assay uses ddPCR technology to examine tumor DNA circulating in the bloodstream. Through a simple blood draw, a patient’s cancer can be analyzed in real-time without the need for additional, invasive biopsies. Liquid biopsy via ddPCR allows for absolute quantification, unparalleled precision and higher overall testing accuracy, giving clinicians the most accurate results for detecting genetic mutations.

Another focus of GoPath Laboratories’ molecular department is the development of assays aimed at detecting the hereditary mutations most commonly associated with certain cancers and syndromes. These panels include BRCANow® for breast and ovarian cancer, LynchNowTM for Lynch syndrome, and Familial Adenomatous Polyposis (FAP) to detect an inherited genetic mutation in which numerous adenomatous polyps form. Several versions of the BRCANow® panel were designed to give patients more options based on their specific needs. These tests include: BRCANow® - BRCA1/2 & BRCA1/2 Deletion/Duplication Analysis for Breast and Ovarian Cancer, the BRCANow® Plus HBOC, and the BRCANow® Extended Comprehensive Risk Panel.

The recent expansion of GoPath’s comprehensive, validated test menu has increased the number of options available to their pharmaceutical clients. In addition to NGS and molecular diagnostics, the company’s in-house laboratory services include FISH, cytogenetics and immunohistochemistry, all of which can be incorporated into creating customized assays for clinical trials and drug development. Clients who enroll in GoPath’s PharmaTargetTM services receive a dedicated project manager, high-quality results reporting, and ongoing consultation from the company’s experienced scientific team. Unlike some of their larger competitors, GoPath Laboratories has the ability to flex and scale as pharma project needs change.

GoPath’s in-depth molecular diagnostics and scientific department only serves to complement the company’s mission to improve patient care. Since GoPath’s inception, every service has been backed by a deep commitment to serve patients by providing clinicians with a better defined diagnosis, more personalized treatment options, and a risk prediction for cancer recurrence that traditional pathology cannot offer. From a wide-range of in-house connectivity solutions to both in-house customer service and billing departments, GoPath Laboratories is well-equipped to serve as leader in cancer diagnostics and pharmaceutical services.

For more information about GoPath Laboratories, visit them at Booth #5027 or online at www.gopathlabs.com.